UBC faculty of medicine researchers have been awarded federal funding as part of Canada’s largest-ever investment in clinical trials.
The Canadian Institutes of Health Research Clinical Trials Fund (CTF) dedicated $250 million across three funding streams to grow and strengthen Canada’s clinical trials infrastructure, training, and research through 2025.
Approximately $60M is being awarded to 22 projects to fund clinical trial phases, designs, and objectives that align with the priorities of the Biomanufacturing and Life Sciences Strategy, including the two UBC-led projects for a total of over $5.5 million.
“Clinical trials help get lifesaving drugs to market. With these new investments, Canadian researchers will have an opportunity to innovate and develop much-needed treatments right here in Canada,” said the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry. “Strengthening the clinical trials ecosystem is an essential part of our government’s Biomanufacturing and Life Sciences Strategy, better preparing us for the future.”
Faculty of medicine recipients and their projects:
Dr. Kevin A. Hay, division of hematology, department of medicine
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Dr. Srinivas Murthy, department of pediatrics
Randomized Embedded Multifactorial Adaptive Platform Trial of Community Acquired Pneumonia